London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: Fallingknife1, 12 Apr 2024 11:00
Last post: Fallingknife1, 12 Apr 2024 11:00
As a hold in an article today. Divis dropped into accounts today so there should be a reinvestment surge, Of course might fall back again after that but I feel about 500p is right for now and any good news could propel TSTL to 600p.
Last post: Monkshood, 28 Mar 2024 09:47
It looks like Tristel have taken advantage of Byotrols financial woes to purchase the IP to one of their formulations they were licencing from them.
'We then agreed to sell to Tristel the underlying IP relating to one of the three previously licensed formulations, the proceeds of which are included in the 'cash-generated' figure above. These two transactions are positive in cash terms but will also result in an exceptional accounting charge to our P&L at year end of £550k, reflecting a write-off of future minimum guaranteed royalties'
Started: Fallingknife1, 26 Feb 2024 07:22
Last post: Fallingknife1, 27 Feb 2024 12:10
Thanks Iron! Liberum are a bit negative on TSTL still rating it a hold but have increased their TP to 420p citing the US ramp up will take longer than planned they think. However they haven't a good record on forecasting TSTl. I think we are starting to see small traction again and hopefully the ex divi fall will be absorbed. I find it always rises into the divi payment date where investors like myself reinvest the divi. The SP can be volatile here of course and there may be more directors sales so best to buy on dips imo.
Fallingk, Totally agree and your comments in the past have proved so accurate. The sp still seems to undervalue this thriving company.
Even the rise today is undervaluing the update. Interim Divi doubled and hopefully the final divi will rise in tandem. That will give me a nice safe yield. Hopefully more buyers will flood in when they see the potential.
Totally agree, excellent results, this should be £6 plus - still below 2021 levels !
Superb results today with an ancillary release of good news on EU approval of the new cache products for an untapped market. Doubling the divi is eye catching which would drive up the yield ordinarily but I expect a jump in the SP today in response. There could be sell on the news people but I didn't detect much positioning in the run up to results. Surely should be 500p and I think value must be 600p now as a growth stock.
Started: Fallingknife1, 8 Feb 2024 09:37
Last post: Fallingknife1, 8 Feb 2024 09:37
And I expect buyers yo flood in pre results which I expect to have continued momentum. Probably a 10% gain to be had in two weeks from here.
Last post: Fallingknife1, 1 Feb 2024 21:20
Ah thanks one desk! Not quite hit it yet though but sentiment is with it. The Canadian deal has been the spur and dare I say it but we might even smash through 500p. 500p itself is almost a 20% gain since the director sells so not to be sniffed at and bound to see some profit taking.
Falling knife - a pretty good forecast of price and date it will be reached! Well done
Started: Fallingknife1, 8 Dec 2023 11:52
Last post: Fallingknife1, 11 Jan 2024 11:25
Thanks Iron. A recovery already seems underway, so it was just a bump in the road. I can see 500p by Feb 22 or whenever the next update is
Fallingk, Value your opinion and hope you are correct. I could not see any reason for selling.
Not so Iron. The chairman is retiring shortly and both are perennial sellers anyway. I think the results will be good in the next trading update. Just a minor blip today.
Well CEO and CFO selling shares.. A vote of no confidence in the company . Given the very low sp for them to sell at this valuation suggests there are problems ahead.
But I expect a bounce to catch divi reinvesting peeps in two weeks. More bang for my buck.
Started: ripley94, 21 Feb 2022 21:32
Last post: Fallingknife1, 1 Dec 2023 18:42
This was 700p at one stage and we know they are flying from the last update. Rating is high but as long as the growth is there investors will pay it. I keep reinvesting the divis and as my largest holding it has served me well.
The spread up to 4.45% today share shows up 2.2% ...450p bid 460 ask.
This share went ex div 23/11/23 so I will get the last payment ( paid 22/12/23 )
The yield shown on this site above 1.5% is less then the 2.3% shown on other sites .
I see it is the back end of 2021 that I maxed out the margin , this purchased on borrowed money.
Rising interest rates this year have made a difference to wisdom of that idea.
But even at 6% cost this one worked out.
Not sure if it pays a div .
Sold them for a target set 440p which failed yesterday. got *445p today ( spread 2.5% )
Only 35 messages on this BB . since my buy 21/2/2022,.
350 to 445 = 27% over 1 year 9 months.
Good luck to those buying into rise hope this keeps rising for you all .
Started: metis20, 22 Nov 2023 08:26
Last post: metis20, 22 Nov 2023 08:26
Just spotted this report on MSN:
https://phys.org/news/2023-11-chlorine-disinfectant-effective-hospital-superbug.html
"One of the primary chlorine disinfectants currently being used to clean hospital scrubs and surfaces does not kill off the most common cause of antibiotic-associated sickness in health care settings globally, according to a new study.
Research by the University of Plymouth has shown that spores of Clostridioides difficile, commonly known as C. diff, are completely unaffected despite being treated with high concentrations of bleach used in many hospitals.
In fact, the chlorine chemicals are no more effective at damaging the spores when used as a surface disinfectant—than using water with no additives.
Writing in the journal Microbiology, the study's authors say susceptible people working and being treated in clinical settings might be unknowingly placed at risk of contracting the superbug.
As a result, and with incidence of biocide overuse only serving to fuel rises in antimicrobial resistance (AMR) worldwide, they have called for urgent research to find alternative strategies to disinfect C. diff spores in order to break the chain of transmission in clinical environments."
Perhaps they are not aware of Tristel’s Cache collection!
Started: ShareSocUK, 14 Oct 2023 11:35
Last post: Fallingknife1, 18 Oct 2023 13:38
Adverse broker comment skittles this yesterday. Appears in its opinion unproven and rating is still high. Can't say I agree and we can see buyers back today without moving the needle admittedly.
At least the divi reinvested will buy more shares. Ridiculous fall and I wonder did some adverse media coverage trigger it?
The sp now back to pre results value..It seems the results were seen as merely satisfactory by the markets. Just wunder what would constitute something positive
Still cannot understand the slump in the sp. These results are impressive yet the market remains mildly satisfied.
ShareSoc is holding its first hybrid event in London on 19th Oct! Hear from Tristel Plc (TSTL) and other healthcare companies like Inspiration Healthcare Group (IHC), Creo Medical Group (CREO), Abingdon Health (ABDX) and GENincode (GENI). Attend in-person or online. 📍🌐 Register: https://bit.ly/3FbyXfe
Started: Fallingknife1, 13 Oct 2023 16:43
Last post: Fallingknife1, 13 Oct 2023 16:43
Recovered from the drop as I guess investors don't want yo be caught with their pants doelwn when results are announce. Hope they are good and they should be with recent progress.
Started: onedesk, 29 Jun 2023 16:10
Last post: onedesk, 29 Jun 2023 16:10
. Watch out for Simply Wall Street if you use it to guide investment. I do not think their analyst forecasts take into account the recent usa situation. In my opinion their analysis is out of date. I think their 'fair price' is up the creek!
Started: Shamtown, 6 Jun 2023 13:28
Last post: ironknut, 10 Jun 2023 12:19
Market was a bit slow reacting to such good news on 5th June. They have "got it" now.
Millions of ponds of shares have just been bought here. That's probably why it's been held down. Should see a TR1 notification soon. Follow the money.
Started: Shamtown, 5 Jun 2023 08:13
Last post: RonnieH, 5 Jun 2023 20:06
Just listened to the investor presentation. Very encouraging.
Tristel ULT possesses numerous USP's over competitors, such as only needing 2mins contact time to disinfect versus 7mins with closest competitor.
Closest competitor sells a machine worth $10,000 that takes up space and needs to be replaced every 7 years while Tristel ULT doesn't require any upfront investment or space and is far more mobile and can be applied to a wider range of appliances.
They have a go to market deal where they will take royalties of sales so they will passively take in profit without any overheads so margin is essentially 100% on Tristel ULT income.
CEO said in his closing statement that although the company is already profitable, today's FDA approval will provide exponential growth for the company going forward.
It has been coming.Wish i had been able to buy more shares when sp feel to silly low valuation.
Been waiting for this a long LONG time. :))
Investor and analyst meeting called later today.
The door is open now to an absolutely massive market of which TSTL should take the majority. The huge increase in sales off the back of this high margin product should transform the company and it's SP.
Started: Dodgiedealer, 5 Jun 2023 07:44
Last post: Alas_Smith, 5 Jun 2023 08:08
News gets better and better.
FinnCap-
'We estimate the NPV of future royalty streams for Tristel ULT in the US to be worth c.£82m or 173p per share, with a range of 117-315p. We raise FY 2024 adjusted pre-tax profit by £0.8m (12%) to £7.6m, with adjusted EPS rising 6% to 12.3p (+23% growth on FY 2023), held back by a higher tax rate. We raise our target price to 500p.'
TRISTEL plc
("Tristel" or the "Company")
FDA De Novo approval
Tristel ULT approved by the FDA as a high level disinfectant for use on endocavity ultrasound probes and skin surface transducers
Tristel expects to gain significant market share in the world's largest ultrasound market
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products utilising proprietary chlorine dioxide technology, announces that the USA Food and Drug Administration ("FDA") has completed its review of the Company's De Novo request for classification (Class II) of Tristel ULT as a high level disinfectant, and has granted its approval for immediate sale.
Tristel DUO, the Company's intermediate level disinfectant approved by the USA Environmental Protection Agency for use on the ultrasound console and the non-invasive parts of the endocavity probe, is now registered in all states of the USA.
The Company estimates that over 215 million ultrasound scans are carried out in the United States annually. Approximately 20% of these scans require high level disinfection and the remainder require low or intermediate level disinfection. With the FDA approval, Tristel has two products approved in the USA that can meet the disinfection needs for all ultrasound scans. This is a unique competitive position.
The United States nationwide launch of Tristel ULT will commence in October this year, following Tristel DUO's market introduction late last year. The Company has already established a manufacturing base with Parker Laboratories Inc., New Jersey, and will utilise Parker's national distribution network for the ultrasound market. Parker is the largest supplier of ultrasound transmission gels in the USA. As both a gel and an appropriate disinfectant must be used in every ultrasound scan procedure, the combination of Tristel and Parker products promises a powerful combination.
Whilst Tristel is a new market entrant in the USA, the Company is very familiar with the competitive landscape which is almost identical in the other 40 plus countries in which Tristel operates. Approximately half of Tristel's global revenue is generated from the ultrasound market.
Further details of the Company's North American commercial strategy will be outlined to equity analysts and investors through a series of presentations over the next few weeks. Further details will be announced in due course.
Paul Swinney, Chief Executive of Tristel, said: "This FDA approval enables our full-blown entry into the United States ultrasound market and is a significant inflection point for the Company. We will now be present in the single largest ultrasound market in the world. This milestone achievement will allow us to significantly increase our global revenue along with our profit potential as we put Tristel's and Parker's resources behind Tristel ULT and DUO in the USA."
Started: Fallingknife1, 20 Feb 2023 12:49
Last post: Scoobydoo321, 21 Feb 2023 14:18
With H2 weighting - they will likely be a beat of forecast, i..e ahead of expec.
It won't wipe away the fall from almost 700p but I hope we can move up from here. I always reinvest the divi so the lowly SP is useful in that respect. USA angle will be useful to boost income. Hopefully no large sales on results from the dynamic duo as it really dents SP progress. Pretty good update!
Started: Scoobydoo321, 2 Feb 2023 14:02
Last post: Me12345, 20 Feb 2023 16:07
They do look expensive but could look really cheap at this level down the line bought some today because if fda approved goes through in June I doubt they will be this price again.
Still expensive
Lowest SP for 3 years with results around the corner.
The meticulous Maynard Paton scrutinises TSTL
Excellent read
https://maynardpaton.com/2023/01/12/tristel-pandemic-disrupted-fy-2022-reiterates-reassuring-10-15-year-sales-growth-ambition-as-us-regulatory-approval-now-relies-upon-fda-negotiation-over-product-batches/
Started: Alas_Smith, 20 Feb 2023 07:53
Last post: Scoobydoo321, 20 Feb 2023 08:56
Well done, Paul. Great results. Looking forward to return back to 400p+
Commenting on the interim results, Paul Swinney, Chief Executive of Tristel, said: "We are delighted to have increased sales by 16% on the first half of last year, above our long-term target for revenue growth.
In all regions the level of diagnostic examinations utilising our products is significantly higher than before the commencement of the pandemic.
We have now entered the North American market, having launched Duo Ophthalmology in Canada, and Duo Ultrasound in the USA under our EPA approval, and expect the FDA's decision on our De Novo submission in June.
The growth prospects for the Group are stronger than ever and we look to the future with confidence."
https://www.londonstockexchange.com/news-article/TSTL/half-year-report/15843025
Look decent to me and reads well.
Started: Alas_Smith, 17 Jan 2022 08:39
Last post: Fallingknife1, 30 Jun 2022 10:26
Good news today. 11 months more and a very significant market becomes fully open with a high barrier to entry. Hopefully will rerate as we move closer to getting approval.
Hopefully it will not be too much longer before news on US licencing is announced.
The RNS issued last June, gives a rough timeline for State by State regulation as end of June 2022
https://www.lse.co.uk/rns/TSTL/regulatory-approval-for-epa-canada-south-korea-o8zrq3x49cax9tb.html
Once approval is in place then it is possible for distribution deals and partnerships in place to translate into sales.
My only commercial dealings with America took 4 years to negotiate and resulted in a massive order that I was unable to fulfil as it was received a month after I had ceased trading. The irony was that I had found new employment for all my staff and it was a very rewarding feeling to assure their new employer of this additional work as I gifted the order to them.
Started: Stockready1, 13 Jan 2022 11:02
Last post: Alas_Smith, 13 Jan 2022 13:10
Tristel PLC is a £230m UK AIM-listed manufacturer of infection prevention, contamination control and hygiene products with a consistent record of revenue, profit and dividend growth. It is one of only a few businesses worldwide that specialises in infection prevention by using Chlorine Dioxide. This is an oxidising agent which destroys unwanted organisms, as opposed to poisoning them, like a traditional cleanser such as Dettol. Its products have 265 patents (as at dec 2020) protecting them and are now used for invasive surgical treatments where traditional sterilisation techniques are just not as effective. The Tristel story began in 1993 when the founding shareholders developed a proprietary chlorine dioxide formulation to be used for the disinfection of flexible endoscopes to replace glutaraldehyde, which was at the time used worldwide for the disinfection of heat-sensitive medical instruments, but was known to be toxic. In 2012 Tristel created its Anistel brand for the animal healthcare market and commenced the manufacture and sale of contamination control products under the Crystel brand for the pharmaceutical and personal care industry. The Group’s most recent major new product initiative is to enter the global hospital surface disinfection marketplace with its Cache Collection. Tristel is now a global business with the US market on its radar where it is in the process of going through the various regulatory hoops for approval. This would be a game changer for the business in terms of scale. It operates with a strong balance sheet which holds net cash, high operating margins, and a royalty model means it has low operating expenses.
Hello sir
I didn't know you posted here and was looking at this stock myself and came here to see other views.
Very interesting read from your comment as always
This looks very attractive level considering where we are today. Over 80% vaccinated Omicron potentially could mean we have seen the back of dangerous covid.
All the indication is the waiting list will be push forward and fast.
So what you think of this considering the current balance sheet and where it is today ? At this very attractive level and technical analysis show a strong support at this level.
Will be interested what you think of the health of this stock going forward.
Many thanks
SR
Elective surgeries are not able to be performed due to shortage of beds in ICU and, currently, surgeons through quarantine regulations. Earliest chance for a revival in revenue for TSTL is with 80% population fully vaccinated (currently on target for 70% by March) and with a consultant led initiative to deal with the backlog.
Cases presenting in A&E currently are serious and in the main are consequential in NOT receiving regular treatment at GP or triage level. Sure there are the same numbers of cases from slips and spills, strokes and heart attacks along with those running out of talent on the roads in the winter but the lack of beds as a result of the unvaccinated needing a few days hospitalisation means that elective surgery for Aunt Mabel and her dodgy hip can be put off as there is no immediate likelihood of death and as she has waited 3 years, another few months won't determine whether she lives or dies.
The GP network is poor, the doctors too eager to pass off patients to specialist care and a health service that is not equipped to cope on a local level with the calls that are made on it.
Just read a buy recommendation in last weeks Money Week. Looks a good company!
Tipped at £4.92!!
So why the big drop in value since please?
Started: MrBeaky, 22 Oct 2021 10:18
Last post: jollyspeculator, 25 Oct 2021 14:12
poxy/token...order(s) of magnitude too small to convince
imv
Nice to see
Last post: onedesk, 21 Oct 2021 17:17
Not selling. Wish I had funds in isa to buy more!
A long term good investment in my opinion
Started: jollyspeculator, 22 Jan 2014 11:02
Last post: jollyspeculator, 21 Oct 2021 16:34
just for the record
Trading Update and notice of results Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products provides a trading update for the six months ended 31 December 2013, ahead of previously upgraded expectations. Tristel addresses three distinct markets: Human Healthcare, Animal Healthcare and Contamination Control, with three distinctively branded product ranges: Tristel, Anistel and Crystel. Tristel has had a strong first half and expects to report encouraging performances from all business segments. Furthermore, following a better than expected December, revenue will be in excess of £6.4m (2012 £4.4m) and pre-tax profit in excess of £0.7m (2012 adjusted pre-tax loss of £0.6m) exceeding levels indicated in the AGM trading update issued in December. The Company has benefited from strong operational cashflow in the first half of the year and net cash at 31 December was £1.4m (2012 net debt of £0.4m). Tristel will announce its half year results on 3 March 2014. Paul Swinney, Chief Executive Officer, comments: "We are delighted with the progress made in the first half of this financial year, in particular the growth seen in sales of Tristel's products used to disinfect non & single lumened instruments, hospital surfaces and within aseptic units. We continue to build upon these successes with confidence that they will continue into the second half and beyond."
Started: PYUECK, 18 Oct 2021 17:43
Last post: jollyspeculator, 21 Oct 2021 16:31
remarkably so...& I spotted how cheap it was c50p lol
no way I'll be back at anywhere near these levels of EV/EBIT
About 8 x revenues, on falling revenues???? Personally I don't buy the reasons for the revenue reduction. The stock seems crazily overvalued. Avoid.
Started: Alas_Smith, 18 Oct 2021 15:52
Last post: Alas_Smith, 18 Oct 2021 15:52
.... well, the explanations for the poor results are plausible enough and the managers have taken the opportunity to add to their exposure. Forward statements are (perhaps deliberately) muted. It has been, I suspect quite a big shock to the managers but at least they have identified non-core assets to eliminate. of most concern to me was the reduction in margin. BUT, the flip side, of course, that in the events that results are poor, might as well get as much out as possible from which improvement should be made in future periods. First point in a decade to have stalled growth.
Not inclined to execute a bargain at this stage but will wait for the dust to settle, look more closely at the numbers and make a considered decision.